Liraglutide
Individualized Obesity Pharmacotherapy
Novo Nordisk · Phase 3 · Completed · Enrollment 193
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Intervention group | n/r | n/r | n/r | n/r | 0 |
| Control Group | n/r | n/r | n/r | n/r | 0 |
A count stays a count. This page does not turn a count into a percent.